Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001

What does the research say about Lactobacillus rhamnosus HN001?

2 health outcomes synthesised

Lactobacillus rhamnosus HN001 has been investigated in two health outcome areas: anxiety and atopic sensitization. The strongest evidence is for reduced anxiety, supported by three studies including a large RCT in pregnant and postpartum women, with a moderate evidence strength. Across outcomes, an effective dose of 6 × 10^9 CFU/day was identified for atopic sensitization, though dose reporting for anxiety was inconsistent.

Strongest evidence

The strongest evidence for Lactobacillus rhamnosus HN001 is for reducing anxiety. Three studies — including a large randomized controlled trial (n=423) in pregnant and postpartum women — all reported beneficial effects, with predominantly small effect sizes. The evidence strength is moderate. No consistent effective dose was identified across these studies.

Mixed or weaker evidence

Evidence for reducing atopic sensitization is low. Three randomized controlled trials examined this outcome; two reported beneficial effects (small and moderate), but only one reached statistical significance. One neutral study involved maternal-only supplementation and showed no effect, suggesting direct infant supplementation may be required. The effective dose was consistently 6 × 10^9 CFU/day.

Effective dose patterns

The only consistent effective dose emerged for atopic sensitization, at 6 × 10^9 CFU/day. For anxiety, doses were not consistently reported or extracted, making dose comparison across outcomes impossible.

Population insights

For anxiety, the evidence comes almost exclusively from pregnant and postpartum women, limiting generalizability to other groups. For atopic sensitization, the research focused on infants (from birth) and their mothers, particularly those at high risk for allergic disease. Maternal-only supplementation was ineffective, while infant supplementation showed some benefit.

Notable caveats

  • For anxiety: only three studies available, two of which were in pregnant/postpartum women, and one was an animal review. Generalizability to other populations is unclear.
  • For atopic sensitization: only one of three RCTs reached statistical significance, and long-term follow-up reporting was inconsistent.
  • No studies reported harmful effects for either outcome.

Frequently asked

  • What is Lactobacillus rhamnosus HN001 good for according to research?
    Research has investigated Lactobacillus rhamnosus HN001 for two outcomes: reducing anxiety and reducing atopic sensitization. The evidence is moderate for anxiety reduction (3 studies, all beneficial) and low for atopic sensitization reduction (3 RCTs, 2 beneficial but only 1 reached statistical significance).
  • What dose of Lactobacillus rhamnosus HN001 is typically used in studies?
    For atopic sensitization, the effective dose was consistently 6 × 10^9 CFU/day across studies. For anxiety, doses were not consistently reported or extracted across the studies, so no typical dose can be identified for that outcome.
  • Who benefits most from Lactobacillus rhamnosus HN001?
    For anxiety, the most studied population is pregnant and postpartum women. For atopic sensitization, infants who received direct supplementation showed potential benefit, while maternal-only supplementation was not effective. Generalizability to other populations is limited.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus HN001?
    Yes. For anxiety, only three studies are available, two focus on pregnant/postpartum women, and one is an animal review — limiting human applicability. For atopic sensitization, only one of three RCTs reached statistical significance, and study durations and long-term follow-up were inconsistently reported.
  • Does Lactobacillus rhamnosus HN001 help with anxiety?
    Three studies report beneficial effects on reducing anxiety, with predominantly small effect sizes. The strongest evidence comes from a large RCT in pregnant and postpartum women. However, the evidence strength is only moderate due to limited study count and population specificity.
  • Does Lactobacillus rhamnosus HN001 help with atopic sensitization?
    Evidence is low. Two of three RCTs reported beneficial effects (small and moderate), but only one was statistically significant. The effective dose was 6 × 10^9 CFU/day, and benefits appeared to require direct infant supplementation rather than maternal-only supplementation.

Most-studied combinations with Lactobacillus rhamnosus HN001

most supplement research is combination research
Also studied with:Lactobacillus rhamnosus MAK79L08R (2)
Back to top